JP7028643B2 - 膜を破壊しないｐ５３活性化ステープルペプチド - Google Patents

膜を破壊しないｐ５３活性化ステープルペプチド Download PDF

Info

Publication number
JP7028643B2
JP7028643B2 JP2017542470A JP2017542470A JP7028643B2 JP 7028643 B2 JP7028643 B2 JP 7028643B2 JP 2017542470 A JP2017542470 A JP 2017542470A JP 2017542470 A JP2017542470 A JP 2017542470A JP 7028643 B2 JP7028643 B2 JP 7028643B2
Authority
JP
Japan
Prior art keywords
peptide
mdm2
peptides
seq
xaa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017542470A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018507689A (ja
JP2018507689A5 (enExample
Inventor
ヨー シン タン
クリストファー ジョン ブラウン
チャンドラ エス ヴァーマ
ガゴ フェルナンド ホセ フェレール
デイヴィッド ピー レーン
トーマス ジョセフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agency for Science Technology and Research Singapore
Original Assignee
Agency for Science Technology and Research Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency for Science Technology and Research Singapore filed Critical Agency for Science Technology and Research Singapore
Publication of JP2018507689A publication Critical patent/JP2018507689A/ja
Publication of JP2018507689A5 publication Critical patent/JP2018507689A5/ja
Application granted granted Critical
Publication of JP7028643B2 publication Critical patent/JP7028643B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2017542470A 2015-02-13 2016-02-15 膜を破壊しないｐ５３活性化ステープルペプチド Active JP7028643B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG10201501119W 2015-02-13
SG10201501119W 2015-02-13
PCT/SG2016/050079 WO2016130092A1 (en) 2015-02-13 2016-02-15 Non-membrane disruptive p53 activating stapled peptides

Publications (3)

Publication Number Publication Date
JP2018507689A JP2018507689A (ja) 2018-03-22
JP2018507689A5 JP2018507689A5 (enExample) 2019-03-28
JP7028643B2 true JP7028643B2 (ja) 2022-03-02

Family

ID=56614951

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017542470A Active JP7028643B2 (ja) 2015-02-13 2016-02-15 膜を破壊しないｐ５３活性化ステープルペプチド

Country Status (6)

Country Link
US (1) US11319344B2 (enExample)
EP (1) EP3256484B1 (enExample)
JP (1) JP7028643B2 (enExample)
CN (1) CN107531759B (enExample)
SG (1) SG11201706562QA (enExample)
WO (1) WO2016130092A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020027585A2 (ko) * 2018-07-31 2020-02-06 주식회사 레모넥스 폴리펩타이드 전달용 조성물
CN112513098A (zh) * 2018-07-31 2021-03-16 雷莫内克斯生物制药有限公司 多肽递送组合物
CN115052614B (zh) * 2019-12-05 2025-10-21 亚洲大学校产学协力团 包含肽或其混合物作为活性成分的用于预防或治疗白塞氏病和类风湿性关节炎的药物组合物
CN111613275B (zh) * 2020-05-26 2021-03-16 中国海洋大学 一种基于rmsd多特征的药物分子动力学结果分析方法
IT202000016807A1 (it) * 2020-07-10 2022-01-10 Humanitas Mirasole Spa Peptidi associati a tumore e loro impiego
EP4228699A1 (en) 2020-10-14 2023-08-23 Dana-Farber Cancer Institute, Inc. Chimeric conjugates for degradation of viral and host proteins and methods of use
WO2024051616A1 (zh) * 2022-09-09 2024-03-14 湖南大学 一种多肽及其制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014055039A1 (en) 2012-10-01 2014-04-10 Agency For Science, Technology And Research Peptides and methods for treating cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8343760B2 (en) 2008-06-05 2013-01-01 University Of Maryland, Baltimore p53 activator peptides
ES2534085T3 (es) * 2009-08-17 2015-04-17 Roche Glycart Ag Inmunoconjugados dirigidos
US20120328692A1 (en) 2011-06-24 2012-12-27 University Of Maryland, Baltimore Potent d-peptide antagonists of mdm2 and mdmx for anticancer therapy
US10081654B2 (en) * 2013-03-13 2018-09-25 President And Fellows Of Harvard College Stapled and stitched polypeptides and uses thereof
US20150010932A1 (en) 2013-07-02 2015-01-08 Salk Institute For Biological Studies Methods for assaying protein-protein interactions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014055039A1 (en) 2012-10-01 2014-04-10 Agency For Science, Technology And Research Peptides and methods for treating cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ACS Chemical Biology (2013) Vol.8, pp.506-512
PLOS One (2013) Vol.8, No.11, e81068, pp.1-16
PLOS One (2014) Vol.9, No.8, e104914, pp.1-8

Also Published As

Publication number Publication date
JP2018507689A (ja) 2018-03-22
CN107531759B (zh) 2021-11-16
SG11201706562QA (en) 2017-09-28
EP3256484A4 (en) 2018-07-25
CN107531759A (zh) 2018-01-02
US20180030090A1 (en) 2018-02-01
US11319344B2 (en) 2022-05-03
EP3256484A1 (en) 2017-12-20
WO2016130092A1 (en) 2016-08-18
EP3256484B1 (en) 2021-06-23

Similar Documents

Publication Publication Date Title
JP7028643B2 (ja) 膜を破壊しないｐ５３活性化ステープルペプチド
JP7191828B2 (ja) がん治療のための組成物および方法
ES2774177T3 (es) Compuestos heterocíclicos y usos de estos
ES2780382T3 (es) Derivados de pirazolopirimidina
JP2025500430A (ja) Ｋ－ＲＡＳ ＧＴＰａｓｅのＧ１２Ｓ、Ｇ１２Ｄ、及び／又はＧ１２Ｅ変異体の共有結合阻害剤
UA124667C2 (uk) Інгібітори syk, фармацевтична композиція, спосіб лікування запального або алергійного розладу, аутоімунного захворювання та раку
CA2981886A1 (en) Ksr antagonists
ES2744198T3 (es) Formulaciones farmacéuticas, procesos, formas sólidas y procedimientos de uso relacionados con 1-etil-7-(2-metil-6-(1H-1,2,4-triazol-3-il)piridin-3-il)-3, 4 dihidropirazino[2,3-b]pirazin-2(1H)-ona
AU2018294314B2 (en) Amorphous and crystalline forms of IDO inhibitors
US20230142739A1 (en) Protein-protein interaction stabilizers
BR112020018094A2 (pt) Compostos de aminopirazina diol como inibidores de pi3k-¿
JP2025509290A (ja) Ｐｃｎａ阻害剤及びその使用
AU2019368263B2 (en) USP7 inhibition
US20150246946A1 (en) Peptides and methods for treating cancer
KR20210091121A (ko) 포스포이노시티드 3-키나아제 (pi3k) 억제제의 결정질 형태
CA3085967A1 (en) 4-(1h-imidazol-5-yl)-1h-pyrrolo[2,3-b]pyridines for use in the treatment of leukaemias, lymphomas and solid tumors
CN115697331A (zh) Taspase1抑制剂及其用途
WO2016172191A1 (en) Compounds, compositions and methods for inhibiting cnksr1
Kaneshige Development of a First-In-Class STAT5 PROTAC Degrader
JP2024502130A (ja) チロシンキナーゼ非受容体１（ｔｎｋ１）阻害剤の形態及び製剤
JP2025508328A (ja) 抗体にコンジュゲートした化学的分解誘導物質とその方法
Pan Discovering small molecule inhibitors targeted to ligand-stimulated RAGE-DIAPH1 signaling transduction
KR20230074784A (ko) 아릴피롤 유도체의 약학적 염
HK40013658A (en) Compositions and methods for treating cancer
EA045276B1 (ru) Соединения, которые взаимодействуют с суперсемейством ras, для лечения рака, воспалительных заболеваний, ras-опатий и фиброзного заболевания

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201026

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210126

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20210303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210303

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210816

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211020

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220124

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220217

R150 Certificate of patent or registration of utility model

Ref document number: 7028643

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250